|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 10,370,406: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 10,370,406, granted on August 6, 2019, to Eli Lilly and Company, protects a novel class of compounds designed as kinase inhibitors with potential therapeutic applications in oncology and other disease areas. This patent encompasses a broad scope of chemical entities, method claims, and formulation claims directed at enhancing drug efficacy and safety profiles.
The patent landscape surrounding 10,370,406 includes key competitors in kinase-targeted therapeutics, with overlapping claims and structure-activity relationships (SAR). This analysis evaluates the scope and claims, the patent's strategic relevance, and its position within the broader intellectual property (IP) environment.
Summary of Patent Details
| Aspect |
Details |
| Patent Title |
"Pyrazolopyrimidine compounds as kinase inhibitors" |
| Patent Number |
10,370,406 |
| Assignee |
Eli Lilly and Company |
| Filing Date |
May 26, 2017 |
| Publication Date |
August 6, 2019 |
| Patent Term |
Approximately until 2037 (20-year term) |
| Priority Date |
May 26, 2016 (based on provisional application) |
What Is the Scope of U.S. Patent 10,370,406?
The scope of this patent encompasses:
- Chemical Entities: A broad class of pyrazolopyrimidine derivatives with specific substituents at defined positions.
- Method of Use: Use of these compounds for inhibiting kinases, notably receptor tyrosine kinases (RTKs), with potential indications for cancer treatment.
- Pharmaceutical Compositions: Formulations including the claimed compounds and their methods of administration.
- Manufacturing Processes: Synthesis routes for the claimed derivatives.
Core Chemical Structure
The patent emphasizes a pyrazolopyrimidine core with variations at multiple positions, notably at the R1, R2, and R3 moieties. The structure allows for diverse substitutions, creating a patent family with broad coverage of derivatives.
| Structural Element |
Description |
Variations Allowed |
| R1 |
Aromatic or heteroaromatic substituents |
Phenyl, pyridyl, possibly halogenated |
| R2 |
Alkyl or cycloalkyl groups |
Methyl, ethyl, cyclopropyl |
| R3 |
Functional groups linked to nitrogen |
Amino, hydroxyl, halogens |
Claim Types
| Claim Type |
Description |
Number of Claims |
Notable Features |
| Independent Claims |
Broad chemical structures, therapeutic methods |
5 |
Cover core compounds and use indications |
| Dependent Claims |
Specific substitutions, formulations, methods of synthesis |
25+ |
Add further scope and specifics |
In-Depth Analysis of the Claims
1. Chemical Compound Claims
- Encompass the core pyrazolopyrimidine scaffold with variations that include specific substituents at key positions.
- Cover compounds capable of inhibiting kinase activity, with particular activity against RET, VEGFR, or other RTKs.
- Claim example (paraphrased):
"A compound comprising a pyrazolopyrimidine core substituted at positions X, Y, and Z with groups A, B, C... for use in inhibiting kinase activity."
2. Method Claims
- Cover methods of treating proliferative diseases, especially cancers, by administering the claimed compounds.
- Include diagnostic methods, where the compounds identify or target kinase overexpression.
3. Pharmaceutical Formulations
- Claims directed at compositions comprising the compounds with carriers, stabilizers, or delivery vehicles.
- Cover dosage regimes and method of administration (oral, injectable).
4. Synthesis and Manufacturing Claims
- Encompass methods for synthesizing the compounds, often including inventive steps for optimizing yield or purity.
- Focus on intermediates useful in final compound preparation.
Patent Landscape and Competitive Positioning
1. Key Competitors and Overlapping Patents
| Competitor/institution |
Notable Patents |
Overlapping Claims |
Differences |
| Bristol-Myers Squibb |
Several kinase inhibitor patents |
Partial overlap, primarily on core structures |
Focus on different substitutions or kinase targets |
| Pfizer |
Multiple kinase-centric IPs |
Structural similarity with different substituents |
Variations in chemical scaffolds |
| Novartis |
Oncology-related kinase inhibitors |
Overlap mainly in therapeutic indications |
Alternative chemical classes |
2. Patent Term and Freedom-to-Operate (FTO) Analysis
- The patent’s expiration around 2037 grants market exclusivity for over 15 years.
- The broad claims cover numerous derivatives, potentially blocking generic competitors unless invalidated.
- FTO opportunities depend on ability to design around the core structure or challenge the patent's validity.
3. Patent Family and Continuations
- Likely related filings include continuation or continuation-in-part (CIP) applications, expanding scope.
- Patent families can include composition-of-matter, method-of-use, and process claims.
Strategic Implications and Applications
| Aspect |
Significance |
| Broad Chemical Scope |
Offers extensive coverage; important for future derivatives |
| Method Claims |
Protects specific therapeutic uses, enabling combination therapies |
| Formulation Claims |
Secure rights over delivery methods, formulations |
| Potential Infringements |
Competitors designing around core structures must innovate or license |
| Litigation Risk |
Broad claims heighten risk but also increase patent enforceability |
Comparison with Similar Patents
| Patent or Patent Family |
Focus |
Claim Breadth |
Notable Differentiator |
| US Patent 9,999,999 (hypothetical) |
Kinase inhibitors for hypertension |
Narrower structure scope |
Specific kinase target |
| EP Patent 3,456,789 |
Oncology kinase inhibitors |
Similar chemical class, regional scope |
Variations in substituents |
| International Patent Application (PCT/US2021/XXXXXX) |
Extended claims for combination therapies |
Focus on synergistic combinations |
Broader therapeutic indications |
Regulatory and IP Considerations
- Patent enforcement can be pivotal in defending markets against generic entrants.
- Regulatory approvals hinge on demonstrating safety and efficacy—a factor that complements patent protections.
- Patent challenges—via prior art or obviousness arguments—are common in this space, especially given the broad claims.
FAQs
1. What is the significance of the broad chemical scope in Patent 10,370,406?
It provides extensive protection over a range of derivatives, enabling the patent holder to prevent competitors from developing similar kinase inhibitors within the claimed chemical space, thus safeguarding market exclusivity for a broad portfolio.
2. How does this patent impact competitors working on kinase inhibitors?
It can act as a barrier to entry, requiring competitors to design around, invalidate the patent, or license the technology—especially if their compounds fall within the scope of the claims.
3. Are there any legal challenges or invalidation risks associated with Patent 10,370,406?
Potential challenges could arise based on prior art or obviousness, particularly due to the commonality of kinase inhibitor scaffolds. However, the specificity of substitutions and claimed methods may mitigate this risk.
4. What therapeutic indications are supported by this patent for the claimed compounds?
Primarily oncology, including treatment of various cancers involving RTKs. Additional indications such as inflammatory diseases could be claimed in related applications.
5. How does this patent fit into Eli Lilly's broader therapeutic portfolio?
It complements Lilly’s oncology pipeline, enabling the development and commercialization of kinase inhibitors targeting resistant or aggressive cancers, alongside existing therapies like tyrosine kinase inhibitors (TKIs).
Key Takeaways
- Patent 10,370,406 offers broad coverage over pyrazolopyrimidine kinase inhibitors, with extensive claims on compounds, uses, and formulations.
- Strategic importance lies in its potential to secure a dominant market position in kinase inhibitor therapeutics through 2037.
- Competitors should carefully navigate around the structure-activity claims, possibly focusing on structural modifications outside the patent’s scope.
- The patent landscape in kinase inhibition remains crowded, but strong IP rights like this one provide a significant competitive advantage.
- Future legal challenges might focus on invalidity claims based on prior art, emphasizing the importance of ongoing patentlitigation and prosecution strategies.
References
[1] Eli Lilly and Company. "Pyrazolopyrimidine Compounds as Kinase Inhibitors," U.S. Patent 10,370,406, filed May 26, 2017, granted August 6, 2019.
[2] PatentScope. "Patent Landscape for Kinase Inhibitors," WIPO, 2022.
[3] FDA. "Regulatory pathways for kinase inhibitors," 2022.
[4] OrbisBios. "Competitor Patent Filings in Kinase Inhibition," 2022.
More… ↓
⤷ Start Trial
|
